NDAINTRAVENOUSPOWDER
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows positron emission tomography.
Indications (1)
Loss of Exclusivity
LOE Date
Jul 28, 2035
114 months away
Patent Expiry
Jul 28, 2035
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 11027031 | Jul 28, 2035 | U-3317 |